还原型谷胱甘肽治疗中、重度慢性乙型肝炎的疗效和安全性研究  

Clinical study of efficacy and safety of reduced glutathione treating midrange and severity chronic hepatitis B

作　　者：邢延清[1] 石磊[1] 冯宁宁[1] 徐斌[1] 王京 李新文[1] 谭莉[1] 张秀华[1] 

机构地区：[1]山东省淄博市中心医院感染性疾病科,淄博255036

出　　处：《药品评价》2008年第7期302-303,324,共3页Drug Evaluation

摘　　要：目的评价还原型谷胱甘肽治疗中、重度慢性乙型肝炎的疗效和安全性。方法将120例中、重度慢性乙型肝炎患者随机分为2组,治疗组应用还原型谷胱甘肽注射液1800mg,每天静脉点滴1次;对照组应用门冬氨酸钾镁30ml,每天静脉点滴1次,疗程均为4周。观察患者临床表现、生化指标和不良事件发生的情况。结果治疗组患者的乏力有效率为88.3%(53/60),纳差的有效率为85%(51/60),与对照组比较,差异有统计学意义(P<0.05)。治疗组患者的血清ALT、AST、血清总胆红素(TBil)的降幅高于对照组(P<0.05),白蛋白(ALB)治疗后增高,与对照组比较,差异有统计学意义(P<0.05)。ALT、AST的复常率治疗组分别为74.6%和76.5%,对照组分别为65.5%和68.8%,差异有统计学意义(P<0.05)。2组均未发现明显的不良反应。结论还原型谷胱甘肽能显著改善中、重度慢性乙型肝炎的临床症状和肝功能指标,不良反应少且轻微。Objective To evaluate the efficacy and safety of reduced glutathione in the treatment of midrange and severity chronic hepatitis B. Methods 120 patients with midrange and severity chronic hepatitis B were randomly divided into the treatment group and control group. In the treatment group, patients were intravenous injected with glutathione 1800 mg qd; in the control group, patients were intravenous injected with potassium magnesium aspartate 30ml qd. The period of treatment was 4 weeks. Results In the treatment group, the effective rate of fatigne and anorexia were 88.3% and 85%, which were significantly higher than that in the control group （P〈0.05）. ALT, AST and TBil were lower in the treatment group （P〈0.05）. The increase of albumin after treatment was more significant in the treatment group than in the control group （P〈0.05）. Severe adverse drug reactions of both groups were not discovered. Conclusion Reduced glutathione can improve the symptom and the liver function index, its adverse effect is rare and light.

关 键 词：肝炎 乙型 慢性 谷胱甘肽 药物治疗 

分 类 号：R512.62[医药卫生—内科学]